The Real opportunity: capitalising on Brazil's push to provide quality healthcare
This article was originally published in Clinica
Calling on a government to ring-fence funding for key health services might not seem exceptional. But when an influential Brazilian parliamentary committee demands that US$3.4bn – one-tenth of the annual federal healthcare budget – be set aside for medtech-intensive priorities, it's a different matter. This is just one indication of the scale of healthcare demand in Brazil and the strong political force that is driving the opportunities in this market. Bernard Murphy reports
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.